CN106265638A - Linderolide H application in preparation treatment or preventing canker sore medicine - Google Patents
Linderolide H application in preparation treatment or preventing canker sore medicine Download PDFInfo
- Publication number
- CN106265638A CN106265638A CN201610805945.XA CN201610805945A CN106265638A CN 106265638 A CN106265638 A CN 106265638A CN 201610805945 A CN201610805945 A CN 201610805945A CN 106265638 A CN106265638 A CN 106265638A
- Authority
- CN
- China
- Prior art keywords
- linderolide
- preparation treatment
- canker sore
- day
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to Linderolide H application in preparation treatment or preventing canker sore medicine.The Linderolide H that the present invention relates to purposes in preparation treatment stomatocace medicine belongs to first public, owing to framework types belongs to brand-new framework types, and its treatment oral ulcer activity is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess prominent substantive distinguishing features, be simultaneously used for treating oral ulcer and obviously have the most progressive.
Description
Technical field
The present invention relates to the new application of compound L inderolide H, particularly relate to Linderolide H in preparation treatment
Or the application in preventing canker sore medicine.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.
Sircus (1975) investigates 1587 people, and prevalence is 20%.As can be seen here, oral ulcer patient is a group the hugest
Body.The cause of disease of recurrent oral ulceration is complicated, the most indefinite, may infect with virus, in antibacterial infection and body
The factor such as parasecretion, immune dysfunction is relevant.
The primary treatment measure of oral ulcer includes that local is treated and whole body therapeutic, due to local treatment toxic and side effects relatively
Low, the people therefore having obtained people can.Although the buccal tablets that the local that occurs in recent years uses carries, easy to use, mouthfeel
And compliance is preferable, such as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., but these medicines are in sterilization, antiinflammatory, pain relieving etc. just
Face emphasizes particularly on different fields.
The compound L inderolide H that the present invention relates to be one within 2014, deliver (Qing Liu, et al.,
Sesquiterpene lactones from the roots of Lindera
Strychnifolia.Phytochemistry, 87 (2013) 112 118.) noval chemical compound, this compound has brand-new bone
Frame type, current purposes merely relates to parasite killing (Qing Liu, et al., Sesquiterpene lactones from the
Roots of Lindera strychnifolia.Phytochemistry, 87 (2013) 112 118.), the present invention is related to
And Linderolide H preparation treatment or preventing canker sore medicine in purposes belong to first public, complete owing to belonging to
New structure type, and it is unexpectedly strong for treatment or preventing canker sore activity, does not exist by other compounds
Provide the possibility of any enlightenment, possess prominent substantive distinguishing features, be simultaneously used for treatment or preventing canker sore obviously has aobvious
The progress write.
Summary of the invention
Do not find in it is an object of the invention to study according to existing Linderolide H that it has treatment or prevention oral cavity
The present situation of the report of ulcer, it is provided that Linderolide H application in preparation treatment or preventing canker sore medicine.
Described compound L inderolide H structure is as shown in formula I:
The Linderolide H that the present invention relates to purposes in preparation treatment or preventing canker sore medicine belongs to first
Open, owing to framework types belongs to brand-new framework types, and its treatment or preventing canker sore activity are unexpectedly strong,
There is not the possibility being provided any enlightenment by other compounds, possess prominent substantive distinguishing features, be simultaneously used for treatment or prevention
Oral ulcer obviously has the most progressive.
Detailed description of the invention
The preparation method of compound L inderolide H involved in the present invention see document (Qing Liu, et al.,
Sesquiterpene lactones from the roots of Lindera
strychnifolia.Phytochemistry,87(2013)112–118.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by concrete real
Execute any restriction of example, but be defined in the claims.
Embodiment 1: the preparation of compound L inderolide H tablet involved in the present invention:
Take 20 g of compound Linderolide H additions and prepare the customary adjuvant 180 grams of tablet, mixing, conventional tablet presses
Make 1000.
Embodiment 2: the preparation of compound L inderolide H capsule involved in the present invention:
Take 20 g of compound Linderolide H additions and prepare the customary adjuvant such as starch 180 grams of capsule, mixing, dress
Capsule makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
The H anti-oral ulcer experimental study of test example 1:Linderolide
1, test objective: manufacture Oral ulcer model with phenol, gives Oral ulcer model rat certain number of times every day
Linderolide H, observes whether Linderolide H is reduced the effect of ulcer.
2, test medicine and reagent
Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd)；Phenol
Animal: Wistar rat, male, body weight 240～280g
3, test method
Take rat 50, male, body weight 240～280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, anesthesia
After plastic dropper (internal diameter: the 3mm) lower end of 90% phenol cotton balls is flat on the cheek film at rats with left bicker about 1mm, burn
Burn 30min, i.e. see the white infringement of about 3mm at this.It is grouped immediately after 24 hours, often group 10, divides 5 groups, i.e. model group (adjuvant
4 times/day, not drug containing)；Linderolide H high dose group (4 times/day, 0.5mg/ time)；Dosage (4 in Linderolide H
Times/day, 0.1mg/ time)；Linderolide H low dose group (4 times/day, 0.02mg/ time)；Positive controls: cydiodine group (4
Times/day, 0.5mg/ time).Linderolide H and cydiodine buccal tablet are ground into powder before use, are administered with flap coverage for degree.
Successive administration 5 days, after before being administered and being administered, next day observes ulcer area size (in terms of the diameter of ulcer) and ulcer healing every time
Situation (ulcer being visible by naked eyes is considered as healing), first administration to last is administered and is recorded as 1,2,3,4,5,6 days respectively.Ulcer
Size t checks, and ulcer healing rate X2 checks.
4, result of the test
Ulcer area compares (table 1): Linderolide H high dose group compares with model group, within the 3rd day, plays examination from being administered
Testing end, corresponding every day compares significant difference；Cydiodine group compares with model group, within the 3rd day, plays off-test from being administered,
Corresponding every day compares significant difference；In Linderolide H, dosage group compares with model group, within the 3rd day, plays examination from being administered
Testing end, corresponding every day compares significant difference；Linderolide H low dose group compares with model group, from being administered the 5th day
Playing off-test, corresponding every day compares significant difference；In Linderolide H, dosage group compares with cydiodine group, from
Being administered the 1st day and play off-test, corresponding every day compares significant difference.
The table 1 impact on rat ulcer area
Note: compare with model group, * p < 0.05, * p < 0.01.
Healing rate (table 2): model group and Linderolide H low dose group play off-test, ulcer on the 1st day from administration
Not healing；And Linderolide H high dose group is from being administered the 4th day, just there is ulcer healing, to off-test, reach 90%；
Cydiodine group, from being administered the 4th day, has ulcer healing, to off-test, reaches 60%；In Linderolide H, dosage group is from giving
Medicine rises on the 5th day, has ulcer healing, to off-test, reaches 40%.
The table 2 impact on rat ulcer healing time
Note: compare with model group, * p < 0.05, * p < 0.01.
5, conclusion
Linderolide H has the effect being obviously promoted oral ulcer healing.
Claims (1)
1.Linderolide H application in treatment or preventing canker sore medicine, described compound L inderolide H ties
Structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610805945.XA CN106265638A (en) | 2016-09-07 | 2016-09-07 | Linderolide H application in preparation treatment or preventing canker sore medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610805945.XA CN106265638A (en) | 2016-09-07 | 2016-09-07 | Linderolide H application in preparation treatment or preventing canker sore medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265638A true CN106265638A (en) | 2017-01-04 |
Family
ID=57710917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610805945.XA Pending CN106265638A (en) | 2016-09-07 | 2016-09-07 | Linderolide H application in preparation treatment or preventing canker sore medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265638A (en) |
-
2016
- 2016-09-07 CN CN201610805945.XA patent/CN106265638A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN106265638A (en) | Linderolide H application in preparation treatment or preventing canker sore medicine | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN102274250B (en) | External patch Chinese medicine for treating phthisis and preparation method thereof | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN109692255A (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute tracheobronchitis | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN106491621A (en) | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine | |
| CN110179860A (en) | A kind of drug of anti-epileptic, preparation method and the usage | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN106619604A (en) | Medicine for treating or preventing dental ulcer, and application of medicine | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN105147676A (en) | Medicine for preventing or treating dental ulcer | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN105412109A (en) | Application of Biscarpamontamine B in preparing drugs for treating or preventing dental ulcers | |
| CN107854472A (en) | Isovitexin is preparing the application in treating or preventing stomatocace medicine | |
| CN103211802A (en) | Novel application of phloroglucinol | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN107837278A (en) | Orientin is preparing the application in treating or preventing stomatocace medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170104 |
|
| WD01 | Invention patent application deemed withdrawn after publication |